Moderna to Build mRNA Vaccine Factory in Kenya
Moderna, a leading biotechnology company specializing in mRNA therapeutics and vaccines, has finalized an agreement with the Government of Kenya to establish an mRNA manufacturing facility in the country, marking its first such facility in Africa. This partnership aims to provide Kenya and the African continent access to mRNA vaccines, enhancing health security and aligning with Moderna's global public health commitments.
The facility, capable of producing up to 500 million doses annually, will not only cater to Kenya's needs but also serve as a resource for the entire African continent. It will enable the manufacturing of vaccines for various health threats, including acute respiratory infections, HIV, Zika, and Ebola, with the flexibility to respond swiftly to public health emergencies.
Both Moderna and the Kenyan government see this agreement as a significant step towards bolstering economic growth and healthcare resilience in the region. President William Ruto expressed the government's commitment to supporting such investments, signaling Kenya's openness to business opportunities.
Moreover, this initiative aligns with Kenya's ambitious 20 by 30 manufacturing vision, which aims to increase the manufacturing sector's contribution to GDP. Operating under a Special Economic Zone status, Moderna's investment underscores Kenya's dedication to attracting foreign investment and fostering economic development.
In addition to the facility in Kenya, Moderna has committed to establishing similar manufacturing facilities in other countries, emphasizing its dedication to global health security. The company aims to address emerging and neglected infectious diseases through its mRNA platform, with a portfolio of vaccine programs targeting various pathogens.
Investor
Outbound region
Inbound region
Industry
Pharmaceutical and biotechnology
Date of record
30 March 2023
